Cures Within Reach

**Our mission is to leverage the speed, safety and cost-effectiveness repurposing – testing already approved therapies for unsolved diseases: driving more treatments to more patients more quickly.** Cures Within Reach is the philanthropic leader in drug, device and nutraceutical repurposing research, which has the potential to transform the lives of patients with unsolved diseases by delivering treatments that can be used in the near-term. Our focus: we find and fund proof-of-concept clinical trials that, once successful, de-risk and catalyze follow-on funding for the larger, confirmatory trials, building the clinical evidence required for regulatory approval or to support off-label use by patients everywhere. **Our Value Proposition** Together with our donor-partners, we bring treatment options to the millions who suffer with unsolved diseases. Our nearly 20-year successful track record in repurposing is complementary to lengthy *de novo* therapy research and has the potential to significantly reduce the time needed to reach as many patients as possible. Together with our donor partners, we are de-risking new treatment options for patients, supporting researchers who have the clinical repurposing ideas to quickly reach patients everywhere. Donor partners choose their desired level of engagement in the design, search and selection process – our experienced team customizes the approach with each donor. Grants starting at $60,000 and up to $250,000 can support a small, proof-of-concept human clinical trial or an expansion of an ongoing trial. We provide: - An expert team providing bespoke services designed to meet your needs - Technical expertise in finding, selecting, de-risking and managing our funded clinical trials - Access to our vast global research network - An efficient, proven RFP process, including external Grant Review Committee members representing research, industry, clinicians and the patient/community voice that support selection and strengthen trial protocols - Project and financial progress reports both during and after the clinical trials